Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.

Published Date: 13 Nov 2023

A novel imaging agent called 68Ga-ABY-025 has the ability to forecast the early metabolic reaction to treatment that targets the human epidermal growth factor receptor 2 (HER2).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

2.

Glioblastoma treatment breakthrough shows promise

3.

A computer-aided diagnostic system for improved detection of breast cancer.

4.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

5.

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot